Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKPRO vs CYTOTEC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits P2Y12 platelet receptor, blocking ADP-mediated platelet aggregation.
Misoprostol is a synthetic prostaglandin E1 analog that binds to prostanoid receptors, leading to inhibition of gastric acid secretion (both basal and stimulated) and increased mucus and bicarbonate secretion, providing mucosal protection. Additionally, it stimulates uterine contractions and cervical ripening.
Reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI),Off-label: Prevention of stent thrombosis in high-risk PCI patients
Prevention of NSAID-induced gastric ulcers in patients at high risk for complications from a gastric ulcer (e.g., elderly, debilitated, or those with concomitant debilitating disease),Medical termination of pregnancy (in combination with mifepristone or methotrexate),Cervical ripening and induction of labor,Management of postpartum hemorrhage (off-label)
1 drop of 0.45% solution in each eye once daily in the evening or as directed by physician.
200 mcg orally four times daily with food for prevention of NSAID-induced gastric ulcers. For termination of pregnancy: 800 mcg vaginally every 12-24 hours or 600 mcg orally as a single dose.
Terminal elimination half-life: approximately 2-3 hours in aqueous humor; systemic half-life is negligible due to low plasma concentrations.
Terminal elimination half-life of misoprostol acid is approximately 20-40 minutes. Due to rapid de-esterification, the half-life of the prodrug is very short (<5 minutes). No accumulation occurs with repeated dosing. In patients with renal impairment, half-life may be prolonged (up to 80 minutes) and dose adjustment may be necessary.
Prodrug; metabolized to active metabolite primarily via CYP2C19, with contributions from CYP3A4, CYP2C9, CYP2B6
Misoprostol is rapidly de-esterified to its free acid (misoprostol acid), which is the active metabolite. Further metabolism occurs via beta-oxidation and reduction of the cyclopentane ring. The primary metabolic enzymes are not well-defined, but esterases are involved in the initial hydrolysis.
Renal excretion of unchanged drug accounts for approximately 1-2% of an administered dose; the remainder is metabolized in ocular tissues and eliminated via nasolacrimal drainage and gastrointestinal tract, with minimal systemic absorption. Biliary/fecal excretion is negligible.
Following oral administration, misoprostol is rapidly de-esterified to misoprostol acid, the active metabolite. Renal excretion of misoprostol acid is approximately 64-73% of the dose (with 11-17% as unchanged acid) over 24 hours. Fecal excretion accounts for about 15% of the dose, primarily as metabolites. Biliary excretion is minimal. The remainder is eliminated as unidentified metabolites.
Approximately 60-70% bound to plasma proteins, primarily albumin.
Misoprostol acid is approximately 80-90% bound to plasma proteins, primarily albumin. The binding is concentration-independent over therapeutic range.
Due to minimal systemic absorption, volume of distribution data is not clinically relevant; for the fraction absorbed, estimated Vd is approximately 0.2-0.4 L/kg.
The apparent volume of distribution of misoprostol acid after oral administration is approximately 3-5 L/kg, indicating extensive tissue distribution. The high Vd reflects rapid uptake into tissues such as gastric mucosa, uterus, and kidneys.
Ocular instillation: systemic bioavailability is low (<1%) due to extensive first-pass metabolism in the nasal mucosa and gastrointestinal tract after nasolacrimal drainage.
Oral bioavailability of misoprostol acid is about 70-80% after oral administration due to extensive first-pass metabolism (de-esterification). Vaginal bioavailability is approximately 3 times higher than oral (area under the curve about 3-fold greater) with prolonged absorption. Sublingual and buccal routes also yield higher bioavailability than oral, with sublingual achieving the highest peak concentrations.
No specific renal dose adjustments recommended; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential systemic accumulation.
No specific dose adjustment recommended for renal impairment based on GFR; use with caution in patients with renal disease due to potential for increased adverse effects.
No specific hepatic dose adjustments recommended; use with caution in severe hepatic impairment (Child-Pugh Class C) due to lack of data.
No specific dosage adjustment based on Child-Pugh score; however, use with caution in hepatic impairment due to limited data.
Safety and effectiveness in pediatric patients have not been established; use is not recommended.
Safety and efficacy not established in pediatric patients; no standard weight-based dosing available.
No specific dose adjustments in elderly; use same as adult dosing, with monitoring for ocular adverse effects.
Dose selection should be cautious, starting at the lower end of the dosing range (e.g., 200 mcg orally twice daily) due to increased sensitivity to gastrointestinal effects and potential for renal impairment in elderly patients.
Efficacy depends on active metabolite formation; reduced efficacy in CYP2C19 poor metabolizers. Avoid use in patients with active pathological bleeding or history of transient ischemic attack/stroke.
Cytotec administration by any route is contraindicated in pregnant women because it can cause abortion or harm to the fetus. Cytotec should not be used for labor induction or cervical ripening outside of an approved clinical setting with strict adherence to recommended dosing and route of administration.
Bleeding risk, especially in patients undergoing surgery; thrombotic thrombocytopenic purpura (TTP) reported; premature discontinuation increases cardiovascular event risk; CYP2C19 poor metabolizers may have reduced efficacy.
Risk of uterine rupture when used for labor induction, especially in women with prior cesarean section or uterine surgery,May cause diarrhea (dose-dependent), which can be severe and require discontinuation,Hydration status should be monitored due to potential for dehydration from diarrhea,Use caution in patients with inflammatory bowel disease or those at risk for gastrointestinal bleeding
Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage); history of transient ischemic attack or stroke; severe hepatic impairment; hypersensitivity to AKPRO or any component.
Pregnancy (for NSAID ulcer prevention indication),Known hypersensitivity to misoprostol or other prostaglandins,Use for labor induction in patients with uterine scarring (relative contraindication)
No known food interactions.
Take with food to decrease incidence of diarrhea, which is dose-related. No specific food restrictions. Avoid alcohol as it may increase GI irritation.
Category C. First trimester: Based on animal studies, may cause fetal harm. No adequate human studies. Second and third trimesters: Risk of premature closure of ductus arteriosus and oligohydramnios with NSAID use after 20 weeks gestation.
Misoprostol (Cytotec) is contraindicated in pregnancy due to its ability to induce uterine contractions and cause fetal harm. First trimester: high risk of fetal death, congenital anomalies (e.g., Moebius sequence), and miscarriage. Second and third trimesters: risk of uterine hyperstimulation, fetal distress, preterm delivery, and fetal demise. Use only for medical termination of pregnancy under strict protocols.
Excreted in breast milk in low amounts (M/P ratio not reported). Use with caution due to potential adverse effects on infant (e.g., gastrointestinal, renal). Short-term use is generally considered acceptable.
Misoprostol is excreted into breast milk in small amounts (M/P ratio approximately 1.0). No adverse effects reported in breastfed infants with short-term maternal use. However, caution is advised with chronic or high-dose use due to potential for diarrhea in the infant. Generally considered compatible with breastfeeding.
No specific dose adjustment recommended for pregnancy; however, avoid use after 20 weeks gestation due to risks of premature ductus arteriosus closure and oligohydramnios. Use lowest effective dose for shortest duration.
Standard dosing for obstetric indications (e.g., cervical ripening) is lower than for peptic ulcer disease and requires adjustments based on gestational age and clinical response. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) may necessitate individualized dosing. For peptic ulcer disease, misoprostol is contraindicated in pregnancy; dose adjustments are not applicable as it should not be used.
AKPRO is a combination ophthalmic solution containing proparacaine 0.5% and fluorescein sodium 0.25%. Use only for diagnostic procedures; never dispense for patient self-administration due to risk of corneal toxicity with repeated use. Apply one drop per eye, then wait 1-2 minutes for maximal anesthesia. Blot excess to reduce systemic absorption. Monitor for corneal epithelial defects after use.
Misoprostol (Cytotec) is a prostaglandin E1 analog used for prevention of NSAID-induced gastric ulcers, cervical ripening, and medical abortion. Always confirm pregnancy status before use due to abortifacient properties. For NSAID ulcer prophylaxis, administer 200 mcg four times daily with food; avoid in women of childbearing potential unless NSAID therapy is essential and patient is using effective contraception. For obstetric use, dosing and route differ (oral, vaginal, buccal, sublingual). Monitor for uterine tachysystole, fever, and diarrhea.
Do not rub your eyes after the drops are applied, as the anesthetic may mask injury.,This medication is for use in a doctor's office only; do not take it home.,Temporary blurred vision and stinging may occur immediately after the drop.,Avoid driving or operating machinery until vision clears completely.,Inform your doctor if you have a history of corneal disease, glaucoma, or allergies to anesthetics.
Do not take this medication if you are pregnant or plan to become pregnant, as it can cause miscarriage.,Take with food to reduce diarrhea, a common side effect.,Report severe abdominal pain, fever, or heavy vaginal bleeding immediately.,For NSAID ulcer prevention, adherence to dosing schedule is critical.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKPRO vs CYTOTEC, answered by our medical review team.
AKPRO is a Prostaglandin Analog (Ophthalmic) that works by Inhibits P2Y12 platelet receptor, blocking ADP-mediated platelet aggregation.. CYTOTEC is a Prostaglandin Analog that works by Misoprostol is a synthetic prostaglandin E1 analog that binds to prostanoid receptors, leading to inhibition of gastric acid secretion (both basal and stimulated) and increased mucus and bicarbonate secretion, providing mucosal protection. Additionally, it stimulates uterine contractions and cervical ripening.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKPRO and CYTOTEC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKPRO is: 1 drop of 0.45% solution in each eye once daily in the evening or as directed by physician.. The standard adult dose of CYTOTEC is: 200 mcg orally four times daily with food for prevention of NSAID-induced gastric ulcers. For termination of pregnancy: 800 mcg vaginally every 12-24 hours or 600 mcg orally as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKPRO and CYTOTEC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKPRO is classified as Category C. Category C. First trimester: Based on animal studies, may cause fetal harm. No adequate human studies. Second and third trimesters: Risk of premature closure of ductus arteriosus a. CYTOTEC is classified as Category C. Misoprostol (Cytotec) is contraindicated in pregnancy due to its ability to induce uterine contractions and cause fetal harm. First trimester: high risk of fetal death, congenital . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.